Pivotal Phase III trial undergoes audits by the FDA and sponsor
Challenge: A pivotal Phase III clinical trial of C1 inhibitor for the prophylactic treatment of hereditary angioedema managed by ARG […]
ARG successfully starts up a Phase II trial within 6 weeks
Challenge: In an economic downturn, small biotech companies often depend on clinical milestones in order to maximize shareholder value and […]
ARG rescues Phase I oncology trial using TrialVista® CTMS
Challenge: A leading specialty pharmaceutical company focused on the development and commercialization of next generation therapies for cancer and immunomodulatory […]
Preferred Provider Status for Atlantic Research Group
Challenge: A specialty biopharmaceutical company targeting the therapeutic power of plasma for the treatment of chronic, life-altering diseases like hemophilia […]